<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030498</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01868</org_study_id>
    <secondary_id>CALGB-60101</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CDR0000069170</secondary_id>
    <nct_id>NCT00030498</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction</brief_title>
  <official_title>Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of erlotinib in treating patients who have&#xD;
      metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies&#xD;
      such as erlotinib may interfere with the growth of tumor cells and slow the growth of the&#xD;
      tumor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of erlotinib in patients with solid tumors and&#xD;
      hepatic or renal dysfunction.&#xD;
&#xD;
      II. Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      hepatic or renal dysfunction (albumin less than 2.5 g/dL, direct bilirubin less than 1.0&#xD;
      mg/dL, any AST, and creatinine normal vs direct bilirubin 1.0-7.0 mg/dL, any AST, and&#xD;
      creatinine normal vs creatinine 2.5-5.0 mg/dL, albumin 2.5 g/dL or greater, AST less than 3&#xD;
      times upper limit of normal, and direct bilirubin less than 1.0 mg/dL).&#xD;
&#xD;
      Patients receive oral erlotinib once daily. Treatment continues in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at&#xD;
      least 6 evaluable patients are treated at that dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities</measure>
    <time_frame>Within the first 4 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Ependymoblastoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Myxopapillary Ependymoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Primary Hepatocellular Carcinoma</condition>
  <condition>Adult Subependymoma</condition>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <condition>Advanced Malignant Mesothelioma</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Adenoid Cystic Carcinoma of the Oral Cavity</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <condition>Recurrent Adult Primary Liver Cancer</condition>
  <condition>Recurrent Anal Cancer</condition>
  <condition>Recurrent Basal Cell Carcinoma of the Lip</condition>
  <condition>Recurrent Bladder Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Recurrent Cervical Cancer</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Esophageal Cancer</condition>
  <condition>Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Recurrent Lymphoepithelioma of the Oropharynx</condition>
  <condition>Recurrent Malignant Mesothelioma</condition>
  <condition>Recurrent Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <condition>Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Mucoepidermoid Carcinoma of the Oral Cavity</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Recurrent Salivary Gland Cancer</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Recurrent Verrucous Carcinoma of the Larynx</condition>
  <condition>Recurrent Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage II Esophageal Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Esophageal Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Adenoid Cystic Carcinoma of the Oral Cavity</condition>
  <condition>Stage IV Anal Cancer</condition>
  <condition>Stage IV Basal Cell Carcinoma of the Lip</condition>
  <condition>Stage IV Bladder Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Esophageal Cancer</condition>
  <condition>Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Lymphoepithelioma of the Nasopharynx</condition>
  <condition>Stage IV Lymphoepithelioma of the Oropharynx</condition>
  <condition>Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Mucoepidermoid Carcinoma of the Oral Cavity</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <condition>Stage IV Salivary Gland Cancer</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Stage IV Verrucous Carcinoma of the Larynx</condition>
  <condition>Stage IV Verrucous Carcinoma of the Oral Cavity</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Untreated Metastatic Squamous Neck Cancer With Occult Primary</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor, including gliomas and the following epithelial&#xD;
             malignancies:&#xD;
&#xD;
               -  Non-small cell lung&#xD;
&#xD;
               -  Mesothelioma&#xD;
&#xD;
               -  Breast&#xD;
&#xD;
               -  Head and neck&#xD;
&#xD;
               -  Esophageal&#xD;
&#xD;
               -  Pancreatic&#xD;
&#xD;
               -  Bladder&#xD;
&#xD;
               -  Prostate&#xD;
&#xD;
               -  Ovarian&#xD;
&#xD;
               -  Anal&#xD;
&#xD;
               -  Colorectal carcinoma&#xD;
&#xD;
               -  Cervical carcinoma&#xD;
&#xD;
               -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Standard curative or palliative therapy does not exist or is no longer effective&#xD;
&#xD;
          -  Epidermal growth factor receptor (EGFR) positive&#xD;
&#xD;
          -  Hepatic or renal dysfunction defined as one of the following:&#xD;
&#xD;
               -  Direct bilirubin 1.0-7.0 mg/dL with any AST&#xD;
&#xD;
               -  Albumin less than 2.5 g/dL&#xD;
&#xD;
               -  Creatinine 2.5-5.0 mg/dL&#xD;
&#xD;
          -  Brain metastases allowed provided patient is asymptomatic, previously treated, has&#xD;
             stable disease for at least 2 months, and is not currently receiving steroid therapy&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No evidence of biliary obstruction&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No evidence of renal obstruction&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No gastrointestinal tract disease that would preclude ability to take oral medications&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No prior corneal abnormalities (e.g., dry eye syndrome or Sjogren's syndrome)&#xD;
&#xD;
          -  No prior congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
          -  No prior abnormal slit-lamp exam using a vital dye (e.g., fluorescein or Bengal-Rose)&#xD;
&#xD;
          -  No prior abnormal corneal sensitivity test (e.g., Schirmer test or similar tear&#xD;
             production test)&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for melphalan or mitomycin)&#xD;
&#xD;
          -  No prior nitrosoureas&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No prior EGFR-targeting therapies, including gefitinib or Imclone C-225&#xD;
&#xD;
          -  At least 3 months since prior suramin&#xD;
&#xD;
          -  More than 7 days since prior grapefruit juice&#xD;
&#xD;
          -  More than 7 days since other prior CYP3A4 inhibitors&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers, substrates, or other inhibitors&#xD;
&#xD;
          -  No concurrent medications known to affect hepatic or renal function, including&#xD;
             antiseizure medication or nonsteroidal anti-inflammatory agents&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonius Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Carcinoma, Verrucous</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Carcinoma, Mucoepidermoid</mesh_term>
    <mesh_term>Esthesioneuroblastoma, Olfactory</mesh_term>
    <mesh_term>Papilloma, Inverted</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Glioma, Subependymal</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
    <mesh_term>Granuloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

